Table 3.
Injection Use by Dollars of Reported Industry Paymentsa
| Reported Industry Payments, $ | Mean (SD) | Injections by Category, % | ||||
|---|---|---|---|---|---|---|
| Total Injections | Aflibercept and Ranibizumab Injections | Bevacizumab Injections | Mean Aflibercept and Ranibizumab | Mean Bevacizumab | SD | |
| 0 (n = 1867) | 583.07 (690.54) | 242.75 (455.00) | 340.33 (425.54) | 29.6 | 70.4 | 33.6 |
| 1–24.99 (n = 264) | 841.08 (789.62) | 442.86 (572.63) | 398.21 (425.54) | 45.5 | 54.5 | 32.8 |
| 25–99.99 (n = 343) | 974.44 (792.91) | 546.90 (615.63) | 427.54 (448.90) | 49.8 | 50.2 | 32.5 |
| 100–199.99 (n = 282) | 906.96 (791.41) | 536.96 (667.21) | 370.00 (398.62) | 48.8 | 51.2 | 33.8 |
| 200–999.99 (n = 140) | 1097.38 (861.50) | 717.31 (669.11) | 380.07 (489.98) | 58.6 | 41.4 | 33.5 |
| >1000 (n = 115) | 1277.00 (893.26) | 950.39 (791.61) | 326.61 (314.66) | 68.4 | 31.6 | 28.1 |
| Correlation coefficient (95% CI)a | 0.22 (0.20 to 0.24) | 0.29 (0.27 to 0.31) | 0.06 (0.04 to 0.09) | 0.25 (0.23 to 0.28) | −0.25 (−0.23 to −0.28) | NA |
Abbreviation: NA, not applicabl e.
a
P < .001 for all comparisons. Correlation coefficients, 95% Cls, and significance calculations were derived using continuous variables.